Mary Matyskiela
About Mary Matyskiela
Title: Vice President of Molecular Sciences
Mary Matyskiela holds the position of Vice President of Molecular Sciences. Her role involves overseeing the molecular sciences division, driving research initiatives, and leading scientific teams. With extensive experience in targeted protein degradation and molecular biology, she brings an expert perspective to this leadership position.
Education and Expertise in Chemistry
Mary Matyskiela earned her B.S. in Chemistry from Yale University. During her undergraduate studies, she conducted research in Dr. Craig Crews' lab, gaining early experience in the field. She further specialized in ubiquitin ligase mechanisms during her graduate work at the University of California San Francisco, working in Dr. David Morgan's lab. Her postdoctoral research at the University of California Berkeley under Dr. Andreas Martin, HHMI, focused on the 26S proteasome's structure and function.
Background in Targeted Protein Degradation
Mary Matyskiela has an extensive background in targeted protein degradation drug discovery. She worked at Celgene and Bristol Myers Squibb for six years, where she eventually became Associate Director of Structural Biology and Proteomics, Oncology West. Her work at these companies involved pivotal research in protein degradation technologies, contributing significantly to the development of new therapeutic strategies.
Research on Molecular Glue Targeting
Mary Matyskiela is known for her research in molecular glue targeting, particularly involving the cereblon-CRL4 complex. Her work has elucidated the molecular mechanisms behind this process and expanded the scientific understanding of molecular glues. She is the author of foundational publications in this field, providing critical insights that have advanced targeted protein degradation research.